Codex
What's Next
Conditional Buy at $73.88: probability-weighted value is $82.40 (+11.5%), with a 2.5% starter position now and scale to 4.0% only if Q1 confirms cleaner earnings quality.
Current Price
Q1 2026 EPS Expectation
FY 2026 EPS Expectation
Upside to Analyst Target ($90.06)
The decisive catalyst is May 6, 2026. If earnings quality improves without sacrificing buyback/dividend pace, the stock can rerate toward peer-high quality multiples; if volatility remains adjustment-heavy, valuation likely stays range-bound.
The Verdict
Verdict: Conditional Buy | Probability-Weighted Value
Expected Return vs $73.88
Expected Gain/Loss Asymmetry (x)
Initial Position Size
Clean Q1/Q2 morbidity trend, variable investment income holds near or above guidance, and buybacks stay aggressive. Market starts underwriting a steadier path to the 15%-17% adjusted ROE framework.
Operating delivery is acceptable but still noisy, keeping MET in a value-with-volatility bucket. Capital return supports downside but no full multiple re-rate.
Claims/investment volatility persists, adjusted-vs-GAAP gap widens again, and investors discount management's medium-term targets as less durable.
condition_type, is not a column in the dataset. sort should contain one column name and optionally a direction (asc or desc). E.g., sort=my_column or sort="my_column desc"
What the market may be missing: MET's buyback-led per-share compounding can still create acceptable returns even without heroic top-line growth, but only if quarterly earnings quality stabilizes enough for investors to trust the ROE path.
Position sizing view: risk/reward is favorable but path risk is real, so this is not a full-size entry. Start at 2.5%, add only after post-May 6 evidence.
No actionable options setup
data/options/realtime_chain.json and data/stan/options/realtime_chain.json both contain Alpha Vantage placeholder sample schema (non-MET synthetic contracts), so there is no reliable strike, expiry, spread, IV, volume, or OI dataset to underwrite a LEAPS/options trade.